Mounjaro®
Starting from £179.99/mo
Start journey Learn moreWhich licensed alternative actually fits your situation, and how to decide
Why Ozempic isn't the alternative you're looking for
A question our prescribers hear most weeks: 'Can I get Ozempic for weight loss?' The short answer is no, not lawfully, and not from a responsible UK pharmacy. Ozempic is semaglutide, and it holds a UK licence for type 2 diabetes management. The NHS medicines page for semaglutide sets this out clearly: Wegovy is the weight-loss formulation of the same drug, approved at a higher dose (up to 2.4mg weekly, or 7.2mg with the newer pen). Prescribing Ozempic for weight loss would be off-label use, something that requires specific clinical justification and cannot happen through a standard online weight-management consultation. If you've read about the two products and wondered how much they actually differ, our guide to how Ozempic and Mounjaro compare covers the detail of how these medicines sit alongside each other. The medicines contain the same active ingredient as Wegovy, but the licensed product, the approved dose and the monitored indication are different things.
The MHRA has been explicit: GLP-1 medicines are not assessed for quick or cosmetic weight loss, and obtaining them without a proper prescription carries real risks, including counterfeit products that have caused hospitalisations.
The two licensed alternatives compared: Mounjaro versus Wegovy
Once you narrow the field to what is actually licensed, the real decision is between Mounjaro and Wegovy. They work differently at a molecular level: Mounjaro activates two gut-hormone receptors (GIP and GLP-1), while Wegovy targets one. Both slow gastric emptying and reduce appetite; both require once-weekly injections. In the SURMOUNT-5 head-to-head trial, tirzepatide produced greater average weight reduction over 72 weeks than semaglutide 2.4mg, and the higher 7.2mg Wegovy dose, approved by the MHRA in April 2026, narrows that gap. You can see the full evidence breakdown on the Wegovy versus Mounjaro page.
| Feature | Mounjaro (tirzepatide) | Wegovy (semaglutide) |
|---|---|---|
| Mechanism | Dual GIP + GLP-1 agonist | GLP-1 agonist |
| Licensed for weight loss in UK? | Yes (MHRA approved) | Yes (MHRA approved) |
| Average weight loss in trials | ~20–21% at 15mg (SURMOUNT-1, NEJM) | ~15% at 2.4mg (STEP 1, NEJM); ~20.7% at 7.2mg |
| NICE recommendation | TA1026: BMI ≥35 + ≥1 comorbidity (NHS route) | TA875: BMI ≥35 + ≥1 comorbidity, specialist service, max 2 years (NHS route) |
| Injection frequency | Once weekly | Once weekly |
| Also available as a tablet? | No | Yes, Wegovy tablets approved June 2026 |
Neither product suits everyone. Eligibility depends on BMI, existing health conditions, other medicines you take, and your medical history. The cost picture also differs by dose and provider; for context on how pricing compares, the Wegovy vs Mounjaro cost page walks through what drives the difference. Our clinical team reviews each consultation individually before any prescription is issued.
A third option that most people miss: the Wegovy tablet
Since June 2026, there is a genuinely new alternative for people who prefer not to inject. The MHRA approved Wegovy tablets (oral semaglutide) as the first GLP-1 weight-loss medicine in tablet form licensed in the UK. The dose escalates from 1.5mg to a 25mg maintenance tablet, taken once daily on an empty stomach. In the OASIS 4 phase-3 trial, participants lost an average of around 13.6% of body weight versus roughly 2.4% on placebo over 64 weeks; those who stayed fully adherent to treatment averaged approximately 17%, a meaningful result for an oral medicine. It requires no refrigeration, which matters to people who travel frequently or simply find injection pens daunting. Eligibility criteria are similar to the injection: adults with a BMI of 30 or above, or 27–29.9 alongside a weight-related health condition. If you'd like to explore all licensed options, the treatment overview page sets them out in full.
What to do next if you're not sure which option fits
The right answer depends on factors a search result cannot assess: your current weight, your health history, any medicines you already take, and your own preferences about injections versus tablets. NICE's guidance for tirzepatide (TA1026) and for semaglutide (TA875) both describe clear clinical criteria, and lower BMI thresholds apply for some ethnic backgrounds under UK guidance. Common questions about eligibility and the consultation process are answered in our FAQs. For a broader look at how these two drugs compare on the evidence, the Ozempic vs Mounjaro page covers what the data actually says, and why the framing of that question is itself misleading. If you have already been using tirzepatide and are wondering whether to switch, our guide to transitioning from Mounjaro to Wegovy explains what that process involves clinically. Which of the licensed options suits you is a clinical decision our prescribers make with you, based on your full picture. Speak to our prescribers through a free consultation to find out where you stand.
Looking to start your weight loss journey?
Take a quick eligibility quiz to explore your options and see how we can support you.